Substantial heterogeneity across studies may reflect differences in study design, population characteristics, timing of IGF-1 measurement, laboratory assays, and inconsistent adjustments for confounding factors such as age, metabolic disorders, and circulating IGFBPs. The gene discussed is IGF1; the disease is metabolic disease.